Publications

Our expertise stems from producing decades of high-impact publications in highly relevant health-screening topics for a range of organisations.

2025

Chilcott J, Bessey A, Bonham JR, Castilla-Rodriguez I, DAvis S, Elliman D, et al. (2025) Methodological and Procedural Considerations for Developing Decision Analytic Models to Assess the Health Economic Impacts of Newborn Bloodspot Screening: A Systematic Methodological Review, Int J Neonatal Screen, 11(4):96.
https://doi.org/10.3390/ijns11040096

O Mandrik, S Whyte, N Kunst, A Rayner, M Harden, S Dias, K Payne, M. Soares. (2025) Modelling the impact of Multi Cancer Early Detection tests: a review of natural history of disease models, arXiv, preprint
https://doi.org/10.48550/arXiv.2502.12351

Villain P, Downham L, Le Bonniec A, Bauquier C, Mandrik O, Nadarzynski T, Donelle L, Murillo R, Tolma EL, Johnson S, Soler-Michel P, Smith R. (2025) Impact of Online Interactive Decision Tools on Women's Decision-Making Regarding Breast Cancer Screening: Systematic Review and Meta-Analysis, J Med Internet Res, Jan 29;27:e65974.
https://doi.org/10.2196/65974

O Mandrik, C Thomas, E Akpan, JWF Catto, J Chilcott. (2025) Home Urine Dipstick Screening for Bladder and Kidney Cancer in High-Risk Populations in England: A Microsimulation Study of Long-Term Impact and Cost-Effectiveness, PharmacoEconomics, 43(4):441-452
https://doi.org/10.1007/s40273-024-01463-y

2024

Cooper KL, Nalbant G, Sutton A, Harnan S, Thokala P, Chilcott J, McNeill A, Bessey A. (2024) Systematic review of newborn screening programmes for spinal muscular atrophy, Int J Neonatal Screen, 10(3):49.
https://doi.org/10.3390/ijns10030049

Cooper KL, Nalbant G, Sutton A, Harnan S, Thokala P, Chilcott J, McNeill A, Bessey A. (2024) Systematic review of presymptomatic treatment for spinal muscular atrophy, Int J Neonatal Screen, 10(3):56.
https://doi.org/10.3390/ijns10030056

H Hill, C Roadevin, S Duffy, O Mandrik, A Brentnall. (2024) Cost-effectiveness of AI for risk-stratified breast cancer screening, JAMA Network Open, 7 (9), e2431715-e2431715.
https://doi.org/10.1001/jamanetworkopen.2024.31715

Chilcott JB, Sutton A, Bessey A, Lombardo S, Visintin C, Marshall J, et al. (2024) Methodological and procedural considerations for developing decision analytic clinical and cost-effectiveness models to assess newborn bloodspot screening, PROSPERO, Study protocol available.
https://www.crd.york.ac.uk/PROSPERO/view/CRD42023461551

2023

Brentnall AR, Atakpa EC, Hill H, Santeramo R, Damiani C, Cuzick J, et al. (2023) An optimization framework to guide the choice of thresholds for risk-based cancer screening, npj Digit Med, 6: 223.
https://doi.org/10.1038/s41746-023-00967-9

Hill H, Kearns B, Pashayan N, Roadevin C, Sasieni P, Offman J, et al. (2023) The cost-effectiveness of risk-stratified breast cancer screening in the UK, British Journal of Cancer, 129: 1801–1809.
https://doi.org/10.1038/s41416-023-02461-1

Catto JW, North B, Goff M, Carter A, Sleeth M, Mandrik O, et al. (2023) Protocol for the YORKSURe prospective multistage study testing the feasibility for early detection of bladder cancer in populations with high disease-specific mortality risk, BMJ Open, 13: e076612.
https://doi.org/10.1136/bmjopen-2023-076612

Catto JWF, Mandrik O, Quayle LA, Hussain SA, McGrath J, Cresswell J, et al. (2023) Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real‐world findings from NHS England between 2013 and 2019, BJU International, 131: 734–744.
https://doi.org/10.1111/bju.15970

Mandrik O, Hahn AI, Catto JWF, Zauber AG, Cumberbatch M, Chilcott J. (2023) Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review, PharmacoEconomics, 41: 633–650.
https://doi.org/10.1007/s40273-023-01256-9

2022

Mandrik O, Thomas C, Whyte S, Chilcott J. (2022) Calibrating Natural History of Cancer Models in the Presence of Data Incompatibility: Problems and Solutions, PharmacoEconomics, 40: 359–366.
https://doi.org/10.1007/s40273-021-01125-3

Essat M, Cooper K, Bessey A, Clowes M, Chilcott JB, Hunter KD. (2022) Diagnostic accuracy of conventional oral examination for detecting oral cavity cancer and potentially malignant disorders in patients with clinically evident oral lesions: Systematic review and meta‐analysis, Head & Neck, 44: 998–1013.
https://doi.org/10.1002/hed.26992

Parak U, Lopes Carvalho A, Roitberg F, Mandrik O. (2022) Effectiveness of screening for oral cancer and oral potentially malignant disorders (OPMD): A systematic review, Preventive Medicine Reports, 30: 101987.
https://doi.org/10.1016/j.pmedr.2022.101987

Thomas C, Mandrik O, Whyte S. (2022) Modelling cost-effective strategies for minimising socioeconomic inequalities in colorectal cancer screening outcomes in England, Preventive Medicine, 162: 107131.
https://doi.org/10.1016/j.ypmed.2022.107131

Mandrik O, Chilcott J, Thomas C. (2022) Modelling the impact of the coronavirus pandemic on bowel cancer screening outcomes in England: A decision analysis to prepare for future screening disruption, Preventive Medicine, 160: 107076.
https://doi.org/10.1016/j.ypmed.2022.107076

Leaviss, J., Harnan, S., Pandor, A., Cantrell, A. (2022) Newborn screening for congenital adrenal hyperplasia. External review against programme appraisal criteria for the UK National Screening Committee.
https://view-health-screening-recommendations.service.gov.uk/congenital-adrenal-hyperplasia/

Whyte S, Thomas C, Chilcott J, Kearns B. (2022) Optimizing the Design of a Repeated Fecal Immunochemical Test Bowel Cancer Screening Programme With a Limited Endoscopy Capacity From a Health Economic Perspective, Value in Health, 25: 954–964.
https://doi.org/10.1016/j.jval.2021.10.002

2021

Thomas C, Mandrik O, Whyte S, Saunders CL, Griffin SJ, Usher‐Smith JA. (2021) Should colorectal cancer screening start at different ages for men and women? Cost‐effectiveness analysis for a resource‐constrained service, Cancer Reports, 4: e1344.
https://doi.org/10.1002/cnr2.1344

Thomas C, Mandrik O, Saunders CL, Thompson D, Whyte S, Griffin S, et al. (2021) The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis, Cancer Prevention Research, 14: 811–822.
https://doi.org/10.1158/1940-6207.capr-20-0620

Mandrik O, Severens JL, Bardach A, Ghabri S, Hamel C, Mathes T, et al. (2021) Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report, Value in Health, 24: 463–472.
https://doi.org/10.1016/j.jval.2021.01.002

2020

Bessey A, Chilcott J, Pandor A, Paisley S. (2020) The Cost-Effectiveness of Expanding the UK Newborn Bloodspot Screening Programme to Include Five Additional Inborn Errors of Metabolism, IJNS, 6: 93.
https://doi.org/10.3390/ijns6040093

2019

Bessey A, Chilcott J, Leaviss J, de la Cruz C, Wong R. (2019) A Cost-Effectiveness Analysis of Newborn Screening for Severe Combined Immunodeficiency in the UK, International Journal of Neonatal Screening, 5. https://doi.org/10.3390/ijns5030028

Mandrik O, Ekwunife OI, Meheus F, Severens JL, Lhachimi S, Uyl‐de Groot CA, et al. (2019) Systematic reviews as a “lens of evidence”: Determinants of cost‐effectiveness of breast cancer screening, Cancer Medicine, 8: 7846–7858.
https://doi.org/10.1002/cam4.2498

2018

Bessey A, Chilcott JB, Leaviss J, Sutton A. (2018) Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme, Orphanet Journal of Rare Diseases, 13: 179.
https://doi.org/10.1186/s13023-018-0921-4

Whyte, S., Thomas, C., Kearns, B., Webster, M., Chilcott, J. (2018) Optimising the cost effectiveness of repeated FIT screening and screening strategies combining bowel scope and FIT screening, Report to the UK NSC, [cited 27 Jun 2024].
https://view-health-screening-recommendations.service.gov.uk/bowel-cancer/

2013

Sharp L, Tilson L, Whyte S, Ceilleachair AO, Walsh C, Usher C, et al. (2013) Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland, BMC Health Serv Res, 13: 105.
https://doi.org/10.1186/1472-6963-13-105

2012

Whyte S, Chilcott J, Halloran S. (2012) Reappraisal of the options for colorectal cancer screening in England, Colorectal Disease, 14.
https://doi.org/10.1111/j.1463-1318.2012.03014.x

2011

Whyte S, Walsh C, Chilcott J. (2011) Bayesian calibration of a natural history model with application to a population model for colorectal cancer, Med Decis Making, 31: 625–641.
https://doi.org/10.1177/0272989X10384738

2007

Tappenden P, Chilcott J, Eggington S, Sakai H, Karnon J, Patnick J. (2007) Option appraisal of population-based colorectal cancer screening programmes in England, Gut, 56: 677–684.
https://doi.org/10.1136/gut.2006.095109

2006

Pandor A, Eastham J, Chilcott J, Paisley S, Beverley C. (2006) Economics of tandem mass spectrometry screening of neonatal inherited disorders, Int J Technol Assess Health Care, 22: 321–326.
https:// doi.org/10.1017/S026646230605121X

2004

Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S. (2004) Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review, Health Technol Assess, 8.
https://doi.org/10.3310/hta8120

1997

Pollitt RJ, Green A, McCabe CJ, Booth A, Cooper NJ, Leonard JV, et al. (1997) Neonatal screening for inborn errors of metabolism: cost, yield and outcome, Health Technology Assessment (Winchester, England), 1: i–iv, 1–202.

Report abuse